pharmaphorum
MARCH 30, 2022
Data from a massive real-world study of asthma patients has suggested that overuse of inhalers is widespread and leading to an elevated risk of severe exacerbations. The results from the SABINA registry programme in more than a million people with the respiratory disease show that 40% of patients were over-using short-acting beta agonist (SABA) inhalers, which are used on demand to open up the airways.
PharmD Live
MARCH 30, 2022
Aging is a privilege, not a guarantee–Chronic Care Management improves quality of life. By Marshall Eidenberg, DO, MBA. As one has the privilege to get older, chronic conditions will go up. Typically, one per decade after one’s 30s. Each situation typically involves one or more medications for each chronic health condition. And with more medicines, the risk of interaction and adverse drug events increases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 30, 2022
Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions in combination cancer immunotherapy. The SKYSCRAPER-02 showed that the combination of the two drugs given on top of chemotherapy was unable to improve progression-free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC – a notoriously hard-to-treat form of lung cancer.
McCreadie Group
MARCH 30, 2022
April 2022 | Mindy Suttlemyre, BS, PhT I was honored to present “Off the Beaten Path: Exploring Opportunities for Technicians within IDS Pharmacy” at McCreadie Group’s 2021 Research Pharmacy Summit. When asked to be a speaker, I was working at The University of Utah/Huntsman Cancer Hospital IDS as the Lead Pharmacy Technician and was eager to. The post My Rewarding Path as a Pharmacy Technician: A Reflection on Career Growth and Opportunity appeared first on McCreadie Group Blog.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 30, 2022
Amazon’s latest push into the healthcare arena is focusing on one of the top new trends in clinical research – the shift towards decentralised trials. Amazon Web Services has teamed up with Thread, a US technology company that has developed a decentralised clinical trials (DCT) platform based on artificial intelligence and machine learning, to enhance and scale up the technology.
Med Ed 101
MARCH 30, 2022
In the case below, I discuss constipation management and how to reduce polypharmacy by targeting medications that cause this adverse effect. KE is a 77-year-old male with a history of GERD, pruritis, insomnia, low back pain, and recent knee replacement. Constipation has been a major problem for this patient and he is taking numerous laxative […].
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Times
MARCH 30, 2022
Report uses input from healthcare professionals to highlight training and support needs, while also warning about departures
pharmaphorum
MARCH 30, 2022
The organisation behind the iconic Canary Wharf development has said it plans to build one of the largest commercial laboratory facilities in Europe as part of a drive to make the east London site a hub for the life sciences sector. Canary Wharf Group has joined forces with science facility developer Kadans on the project, which will kick off with the construction of a 22 storey, 750,000 sq. ft. building dedicated to a combination of wet lab and office space.
Pharma Times
MARCH 30, 2022
ProKnow was chosen to enable healthcare providers to benchmark treatment metrics against best practice and support clinical excellence
pharmaphorum
MARCH 30, 2022
Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology and immunology/inflammation. The sizeable alliance includes up to $6 billion in back-loaded milestone payments, and Sanofi says it is also considering making a $100 million investment in IGM stock.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
114 
Let's personalize your content